The Most Explosive Product Right Now?

Join TradeAlgo's Free Live Trading Session ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ [EARN WHILE YOU LEARN! JOIN OUR FREE LIVE TRADING SESSION!]( Hello investor, The Most Explosive Product Right Now? Well, that didn’t last long. The enthusiasm from Nvidia’s blockbuster earnings was short-lived. The stock market fell yesterday after data showed business activity jumped and a rising inflation. Meaning? Rate cuts are unlikely to come soon. While Nvidia jumped 9% on the day, all megacap stocks were down for the day. The Dow Jones plunged 1.5%. The S&P 500 fell 0.74% while the Nasdaq had the smallest loss at 0.39%. As a result, traders moved the first rate cut to December from November. The S&P Global flash May composite purchasing managers index jumped to 54.4 for the highest level since April 2022. It beat Wall Street estimates, and it was a sharp jump in the second quarter. (Source: Bloomberg) Manufacturing output also expanded quicker. All of this indicate that it’ll be tough for inflation to cool down to the 2% target. So, rates are likely to stay higher for longer. Moreover, initial applications for unemployment benefits fell last week. For those that receive unemployment benefits, the number remained almost unchanged at 1.79 million. They remain at a historically low level. (Source: Bloomberg) All in all, it will be tough for inflation to ease to the 2% target with the economy running this strong. That becomes the focal point of the market — despite Nvidia’s results. Wall Street views rate cuts as a critical catalyst to boost tech earnings. Wall Street now prices in just one rate cut this year — a steep drop from at least six cuts at the beginning of the year, with the first cut happening in March. The Most Explosive Product Right Now? Today’s Stock Pick: RxSight (RXST) This is the company to watch out for. Cataract surgery is the most common surgical procedure in the world — with 20+ million surgeries performed annually. However, it is difficult for surgeries to offer a perfect 20/20 vision for every patient. Only 60% of cataract patients achieve the targeted vision, and even lower percent achieve proper vision at all distances. Enter RxSight. It offer FDA-approved Light Adjustable Lens system which is the world’s first and only commercially available intraocular lens (IOL) technology. In short… It allows surgeons to customize and optimize visual acuity for every unique eye after cataract surgery. So, if it doesn’t achieve a perfect vision, RxSight’s LAL makes it possible for then to adjust to the perfect vision. (Source: RxSight) The technology was designed by a Nobel Prize winning scientist that changes the shape and power of the lens that controls ultraviolet (UV) light exposure. (Source: RxSight) The difference between RxSight LAL and the standard surgery is enormous. Only 36% of the control group achieved a 20/20 or better vision (using older technologies) while RxSight LAL achieved 70.1% — two times more. (Source: RxSight) So, it is almost no brainer to go with RxSight’s technology. As a result, its LAL units exploded since the fourth quarter of 2021. It went from just 2,959 to 20,218 in only nine quarters! That’s more than 1,000% growth. (Source: RxSight) Naturally, its revenue grew rapidly with the 82% growth rate in the recent year: (Source: RxSight) Moreover, you can see revenue growth rate staying consistently above 40% in the last few quarters: (Source: MacroTrends) Bottom line: RxSight offers a rare opportunity to invest in an emerging technology at its early stage. The company is the only player in this exploding space, and it is sure to watch its revenue growing over the next few quarters. [EARN WHILE YOU LEARN! JOIN OUR FREE LIVE TRADING SESSION!](     © All Rights Reserved, Trade Alliance [Unsubscribe]( | [Manage Preferences](